Summary

OmniVision AG, in consultation with Swissmedic, is precautionarily recalling batches 10138 and 10140 of the eye gel Lacri-Vision® from the market. The reason is a suspected compromise of sterility due to a deviation at the manufacturer. The measure is taken preventively; no adverse effects have been reported to date. Affected patients should discontinue use of the product and return it to their pharmacy or medical practice. The recall was announced on May 7, 2026 in Bern.

Persons

  • OmniVision AG (pharmaceutical company)

Topics

  • Drug safety
  • Batch recall
  • Swissmedic regulation

Clarus Lead

The precautionary recall signals a functioning surveillance system: Swissmedic and the manufacturer respond to potential quality defects before patients are harmed. For users of Lacri-Vision®, immediate action is required – the affected batches must be withdrawn from circulation without delay.

Detailed Summary

The recall affects two specific batches of an eye gel medication. The deviation was identified during manufacturing and could compromise the sterility of the product – a critical quality characteristic for eye preparations, as contaminated solutions can lead to eye inflammation or more serious complications.

Affected patients receive return instructions through their sources of supply (pharmacies, medical practices). OmniVision provides contact information ([email protected], www.omnivision.ch) for inquiries. Swissmedic documents the case publicly in its batch recall database.

Key Points

  • Two batches (10138, 10140) of Lacri-Vision® eye gel are affected
  • Reason: Suspected sterility compromise due to manufacturing deviation
  • Status: Precautionary recall with no harm reports to date
  • Action: Return to pharmacy/medical practice required

Critical Questions

  1. Evidence: How was the manufacturing deviation discovered – through routine testing or external notification? What is the specific deviation?

  2. Conflicts of Interest: Is this a voluntary recall by OmniVision or a measure requested by authorities?

  3. Causality: Are there epidemiological data on how many patients received these batches? How long were they in circulation?

  4. Feasibility: How is it ensured that patients without a medical prescription identify the return locations? Is replacement supply available for affected users?

Source List

Primary Source: State Secretariat for Economic Affairs (SECO) / Federal Council – Batch Recall Lacri-Vision® Eye Gel – https://www.news.admin.ch/de/newnsb/vGbCEOlZed05lYeZPUTYD

Supplementary Sources:

  1. Swissmedic – Batch Recall Database: https://www.swissmedic.ch
  2. OmniVision AG – Information Letter: https://www.omnivision.ch

Verification Status: ✓ 07.05.2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 07.05.2026